Olema Pharmaceuticals News

Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge

TipRanksApr 12 11:55 ET

FATE, ALPN and RLAY Are Among After Hour Movers

Seeking AlphaApr 10 17:20 ET

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and

GlobeNewswireApr 8 16:30 ET

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, develo

GlobeNewswireApr 2 16:29 ET

Express News | Goldman Sachs Initiates Coverage On Olema Pharmaceuticals With Buy Rating, Announces Price Target of $24

Moomoo 24/7Apr 2 07:09 ET

Olema Pharmaceuticals(OLMA.US) Director Sells US$219.4K in Common Stock

$Olema Pharmaceuticals(OLMA.US)$ Director Harmon Cyrus sold 20,000 shares of Common Stock on Mar 28, 2024 at an average price of $10.97 for a total value of $219.4K.Source: Announcement What is statem

moomoo NewsMar 29 17:41 ET

Form 144 | Olema Pharmaceuticals(OLMA.US) Director Proposes to Sell 219.33K in Common Stocks

SEC FILLINGS DISCLOSED/ Mar 28, $Olema Pharmaceuticals(OLMA.US)$ Director Harmon Cyrus intends to sell 20,000 shares of its common stock on Mar 28, with a total market value of approximately $219.33K.

moomoo NewsMar 28 11:10 ET

Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment

TipRanksMar 12 09:45 ET

Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $21 Price Target

Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals with a Outperform and maintains $21 price target.

Analyst UpgradesMar 12 08:18 ET

Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TipRanksMar 12 08:05 ET

Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity

TipRanksMar 12 08:05 ET

Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 12 06:49 ET

Express News | HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $25

Moomoo 24/7Mar 12 06:39 ET

Olema Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/12/2024 88.68% HC Wainwright & Co. $28 → $25 Maintains Buy 01/30/2024 50.94% Citigroup → $20 Initiates

BenzingaMar 12 06:33 ET

Optimistic Outlook on Olema Pharmaceuticals: A Comprehensive Analysis of Palazestrant's Clinical Advancements and Future Potential

TipRanksMar 12 06:26 ET

Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals' Palazestrant

TipRanksMar 11 20:25 ET

Express News | Olema Pharmaceuticals Q4 EPS $(0.49) Misses $(0.48) Estimate

Moomoo 24/7Mar 11 16:04 ET

Press Release: Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update -- Presented compelling clinical results for palazestrant both as a monotherapy and i

Dow JonesMar 11 16:03 ET

Olema Pharmaceuticals 4Q Loss/Shr 49c >OLMA

Olema Pharmaceuticals 4Q Loss/Shr 49c >OLMA

Dow JonesMar 11 16:03 ET

Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year

Seeking AlphaMar 10 13:08 ET